Patients suffering from dystonia, an uncommon yet potentially crippling movement disorder, get better results if they begin deep brain stimulation therapy sooner rather than later, according to an international study published in the March issue of the Journal of Neurology.
“Our data suggest that patients who begin treatment earlier in the disease process may expect a better general outcome than those with longer disease duration. Also, age at surgery appears to influence the time necessary to achieve the best clinical response, meaning that older patients need more time before reaching their potential benefit,” said Michele Tagliati, MD, director of the Movement Disorders Program at Cedars-Sinai Medical Center and the article’s senior author.
Dystonia causes muscles to contract, with the affected body part twisting involuntarily and symptoms ranging from mild to severe. The Food and Drug Administration approved deep brain stimulation as a therapy for certain treatment-resistant dystonias in 2003 after approving it for essential tremor in 1997 and Parkinson’s disease in 2002. The procedure recently was approved on a limited basis for obsessive-compulsive disorder.
“We knew from earlier work that younger patients with shorter disease duration had better clinical outcomes in the short term. Now we know they fare best in the long term, as well. Our study uniquely showed that age and disease duration play complementary roles in predicting long-term clinical outcomes. The good news for older patients is that while they may not see the rapid gains of younger patients, their symptoms may gradually improve over several years,” said Tagliati, who is considered one of the world’s top experts on the therapy.
The study involved 44 patients with generalised dystonia ranging in age from 10 to 59 years, with a midpoint of 31 years. Disease duration ranged from two to 42 years, with a midpoint of 15 years. There were three key clusters of patients whose medical records were analysed:
- Those younger than 27 and who had suffered from dystonia fewer than 17 years (17 patients);
- Those older than 27 but who had suffered fewer than 17 years (eight patients);
- Those older than 27 and who had suffered more than 17 years (19 patients).
Patients were evaluated on a standard dystonia rating scale at three intervals: after treatment began (baseline) and at one- and three-years. Specific results included:
- Every patient experienced overall improvement in motor function – their ability to control muscles and movements – after surgery and device activation. All ratings of individual body regions or functions such as speech (sub-scores) improved significantly at one year. Further gains were seen at three years;
- Three patients’ overall outcomes declined, with mild worsening of some symptoms between years one and three;
- Five more patients had some worse sub-scores at year three but continued to show overall improvement and did not return to their pre-treatment impairment levels;
- Patients older than 27 at the time of surgery showed an additional 10 per cent average improvement between years one and three of therapy;
- Thirty-two patients were taking prescription drugs before surgery but this number declined by 52 per cent at year one and 80 per cent at year three.
The stimulation device consists of electrical leads implanted in the brain and an electrical pulse generator located near the collarbone. The stimulator is programmed with a remote, hand-held controller to modulate abnormal nerve signals that cause dystonia’s uncontrolled muscle contractions.
Dystonia is less common than Parkinson’s disease – and has been more of a medical mystery, even among many movement disorders specialists. Proper surgical placement of the stimulation device and precise, individualised programming are critical to successful treatment, said Tagliati, who leads an educational course on deep brain stimulation programming every year at the American Academy of Neurology meetings. He said many cases of seemingly “failed” therapy can be corrected through expert fine-tuning of the device, along with optimal medication management.
The study was funded in part by a grant from the Bachmann-Strauss Dystonia & Parkinson Foundation and the Mariani Foundation for Paediatric Neurology. Although Tagliati and other authors receive speaking honoraria and consulting fees from Medtronic Inc., none are related to this study.
For more information on neurological disorders that affect movement, and their treatments, see Neurological Rehabilitation and Movement Disorders.